Pharmaceutical - Biosimilars

Filter

Current filters:

Biosimilars

Popular Filters

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

Rheumatologists have mixed views on Xeljanz's effect on structural damage and safety, but 80% prescribe it

03-11-2014

Although 80% of rheumatologists surveyed by data and research firm Decision Resources Group prescribe…

Anti-Arthritics/RheumaticsBiosimilarsGlobalPfizerPharmaceuticalResearchXeljanz

Rheumatologists welcome novel biologics for systemic lupus erythematosus, survey finds

Rheumatologists welcome novel biologics for systemic lupus erythematosus, survey finds

16-10-2014

Rheumatologists would welcome novel biologics for the treatment of systemic lupus erythematosus (SLE),…

BenlystaBiosimilarsGlaxoSmithKlineHealthcareNeurologicalPharmaceuticalResearchUSA

Merck Serono on track with pharma strategy

Merck Serono on track with pharma strategy

18-09-2014

Germany’s Merck KGaA says that its biopharmaceutical division - Merck Serono - is well on track with…

ataciceptBiosimilarsFinancialGermanyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearchTH-302

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

EU approval for Boehringer and Lilly’s insulin glargine biosimilar

EU approval for Boehringer and Lilly’s insulin glargine biosimilar

10-09-2014

The European Commission granted marketing authorization for US drug major Eli Lilly and family-owned…

AbasriaBasaglarBiosimilarsBoehringer IngelheimDiabetesEli LillyEuropeInsulinLantusPharmaceuticalRegulationSanofi

Brazilian antitrust agency approves Bionovis and Merck's partnership deal

Brazilian antitrust agency approves Bionovis and Merck's partnership deal

28-08-2014

The General Superintendent of the Brazilian Antitrust Agency (CADE) approved the agreement between the…

BionovisBiosimilarsBrazilLicensingMerck KGaAPharmaceuticalResearch

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

Actavis announces proposed Senior Leadership Team

Actavis announces proposed Senior Leadership Team

14-05-2014

US generics major Actavis (NYSE: ACT) has announced the proposed senior management team that will lead…

ActavisBiosimilarsBoardroomForest LaboratoriesPharmaceuticalUSA

Merck KGaA may look to biosimilars and acquisitions for growth

Merck KGaA may look to biosimilars and acquisitions for growth

12-05-2014

German pharma and chemical major Merck KGaA has said it is planning to invest in innovations to ensure…

BiosimilarsLicensingMerck KGaAMergers & AcquisitionsPharmaceutical

India now making moves into pharma innovation

India now making moves into pharma innovation

03-03-2014

In what must be seen as a significant change in focus, India is now seeing a surge of innovative research…

Asia-PacificBiosimilarsIndiaMarkets & MarketingPharmaceuticalResearch

Sanofi sues Eli Lilly over Lantus patent infringement

Sanofi sues Eli Lilly over Lantus patent infringement

31-01-2014

French drug major Sanofi says it has filed a patent infringement suit against USA pharma firm Eli Lilly…

BiosimilarsDiabetesEli LillyLantusLegalNorth AmericaPatentsPharmaceuticalSanofiUSA

GVK BIO to acquire US CRO Aragen Bioscience

30-01-2014

Asia’s leading small-molecule contract research organization (CRO), GVK BIO, has reached agreement…

Aragen BioscienceBiosimilarsGVK BIOMergers & AcquisitionsPharmaceutical

Brazil initiates public consultation on interchangeability of biosimilar drugs

Brazil initiates public consultation on interchangeability of biosimilar drugs

17-01-2014

Biosimilar drugs, also known as follow-on biologics, may soon be substituted in place of the reference…

BiosimilarsBrazilPharmaceuticalRegulationSouth America

Promising late-stage GI drugs could stabilize global market decline; report

16-01-2014

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis…

BiosimilarsGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Back to top